Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Fulgent Genetics Inc. (FLGT)

19   0.72 (3.94%) 02-21 16:00
Open: 18.41 Pre. Close: 18.28
High: 19.33 Low: 18.11
Volume: 181,762 Market Cap: 355M
Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 19.34 - 19.435 19.435 - 19.532
Low: 17.895 - 17.99 17.99 - 18.086
Close: 18.842 - 18.998 18.998 - 19.155

Technical analysis

as of: 2020-02-21 4:30:06 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 24.06     One year: 28.10
Support: Support1: 15.29    Support2: 12.00
Resistance: Resistance1: 20.60    Resistance2: 24.06
Pivot: 16.76
Moving Average: MA(5): 18.97     MA(20): 15.84
MA(100): 12.89     MA(250): 9.58
MACD: MACD(12,26): 1.47     Signal(9): 1.14
Stochastic oscillator: %K(14,3): 79.01     %D(3): 86.44
RSI: RSI(14): 68.68
52-week: High: 20.60  Low: 4.38  Change(%): 315.5
Average Vol(K): 3-Month: 26342  10-Days: 26528

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
FLGT has closed below upper band by 22.2%. Bollinger Bands are 109.3% wider than normal. The large width of the bands suggest high volatility as compared to FLGT's normal range. The bands have been in this wide range for 9 bars. This is a sign that the current trend might continue.

Headline News

The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.

The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: XLRN ) Agile Therapeutics Inc (NASDAQ: AGRX )( announced securing of loan facility) Allergan plc (NYSE: AGN ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE ) Cytokinetics, Inc. (NASDAQ: CYTK ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nevro Corp (NYSE: NVRO ) Novartis AG (NYSE: NVS )(announced priority review for its lung cancer drug) Pacira Biosciences Inc (NASDAQ: PCRX ) PAVmed Inc (NASDAQ: PAVM )(PAVmed's EsoGuard Esophageal DNA test was accorded Breakthrough Device designation) Penumbra Inc (NYSE: PEN ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Seattle Genetics, Inc. (NASDAQ: SGEN )(announced positive data readout for ADC in bladder cancer) Syneos Health Inc (NASDAQ: SYNH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 11) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Brickell Biotech Inc (NASDAQ: BBI ) Endologix, Inc. (NASDAQ: ELGX ) Enzo Biochem, Inc. (NYSE: ENZ )( received New York State approval for its gynecological …

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Diagnostics Research
Shares Out. (M) 18.71
Shares Float (M) 9.75
% Held by Insiders 60.11
% Held by Institutions 28.24
Shares Short (K) 290
Shares Short P. Month (K)

Stock Financials

EPS -0.120
Book Value (p.s.) 2.920
PEG Ratio 3.02
Profit Margin -7.27
Operating Margin -3.52
Return on Assets (ttm) -1.1
Return on Equity (ttm) -4.1
Qtrly Rev. Growth 83.9
Gross Profit (p.s.) 0.569
Sales Per Share
EBITDA (p.s.) 0.056
Qtrly Earnings Growth
Operating Cash Flow (M) 6.41
Levered Free Cash Flow (M) 6.41

Stock Valuations

P/E -158.33
P/E Growth Ratio 0.04
P/BV 6.51
P/S 11.65
P/CF 55.46

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.